*仅供医学专科东谈主士阅读参考

2024 ASCO 规模重磅斟酌发达行将亮相，快来参与投票~

2024年ASCO大会召开在即，多项乳腺癌规模重磅斟酌发达行将惊艳亮相，为了让更多医疗同谈更好地晓悟本次大会的学术魔力，咱们将筛选一些具有代表性的斟酌进行亮点解读，哪些斟酌也恰是您心中所念念，不错在著作下方进行投票选拔，接下来请全球奉陪复旦大学附属病院张剑教师的脚步，第一本领抵达现场共同“围不雅”大会中这些备受瞩蓄意斟酌发达。

问题与对应摘抄

Q1

T-DXd用于HER2阳性晚期二线诊治OS延迟若干？接收T-DXd诊治达到CR的患者能否会已毕遥远疾病缓解？

1025：Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03

DESTINY-Breast03的最重生涯成果：T-DXd与T-DM1在HER2+回荡性乳腺癌患者的相比

讲者：Erika P. Hamilton, MD | Sarah Cannon Research Institute

1023：Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03

DESTINY-Breast-01, -02,和-03斟酌汇总分析：T-DXd在HER2+回荡性乳腺癌患者中的最好证据缓解率

讲者：Cristina Saura, MD, PhD | Vall d’Hebron University Hospital, Vall d'Hebron Institute of Oncology

Q2

DB06：T-DXd用于HER2低抒发晚期乳腺癌未经化疗的患者，疗效是否会更好？HER2超低抒发患者能否获益？

LBA1000：Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

DB06：在既往接收过内分泌诊治的HR+/HER2低抒发或HER2超低抒发mBC患者中相比T-DXd和大夫选拔的化疗

讲者: Giuseppe Curigliano, MD, PhD | University of Milan and European Institute of Oncology, IRCCS

Q3

Dato-DXd±IO用于早期TNBC新接济诊治的疗效怎样？

LBA509：Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.

Dato-DXd新接济诊治的病理学悉数缓解（pCR）率：来自I-SPY2.2斟酌的成果

讲者:Jane Lowe Meisel, MD | Winship Canter Institute of Emory University

LBA501：Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.

Dato-DXd蚁集度伐利尤单抗新接济诊治的pCR率：来自I-SPY2.2斟酌的成果

讲者：Rebecca Arielle Shatsky, MD | University of California, San Diego Medical Center

Q4

CDK4/6贬抑剂约略跨线使用？

LBA1001：Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

postMONARCH主要结局：阿贝西利+氟维司群 vs氟维司群单药用于既往CDK4/6贬抑剂蚁集内分泌诊治发达的HR+/HER2-aBC

讲者: Kevin Kalinsky, MD, MS | Winship Cancer Institute of Emory University

Q5

TROP2 ADC蚁集IO用于HR+/HER2-晚期乳腺癌

LBA1004：SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

SACI-IO HR+：在HR阳性/HER2阴性回荡性乳腺癌患者中评估SG蚁集或不蚁集帕博利珠单抗的立地II期测验

讲者:Ana Christina Garrido-Castro, MD | Dana-Farber Cancer Institute

Q6

DB09的预报？T-DXd单药或蚁集帕妥珠单抗用于HER2阳性晚期一线诊治

1009：DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.

DESTINY-Breast07：德曲妥珠单抗（T-DXd）单药或蚁集帕妥珠单抗在既往未接收过诊治的HER2阳性回荡性乳腺癌中的剂量彭胀中期分析

讲者：Fabrice Andre, MD, PhD | Gustave Roussy, Université Paris-Saclay

Q7

SKB264用于晚期TNBC诊治，首个III期临床公布

104：Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.

OptiTROP-Breast01：SKB264/MK-2870用于既往接收过诊治的局部复发或回荡性TNBC患者

讲者:Ying Fan, MD | Cancer Hospital Chinese Academy of Medical Sciences

Q8

ARX788诊治HER2阳性晚期乳腺癌的首个III期临床斟酌

1020：ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).

ACE-Breast-02：ARX788蚁集拉帕替尼及卡培他滨诊治HER2阳性aBC的要道II/III期测验

讲者：Xichun Hu, MD, PhD | Fudan University Shanghai Cancer Center

Q9

新靶点ADC药物斟酌

3013：9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.

9MW2821是一种nectin-4抗体药物偶联物(ADC)，在晚期实体瘤患者中的专揽：来自1/2a期斟酌的成果

讲者：Jian Zhang | Fudan University Shanghai Cancer Center

1005：Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202

EV-202斟酌中Enfortumab vedotin在TNBC和HR+/HER2-乳腺癌队伍的专揽

讲者：Antonio Giordano, MD, PhD | Dana-Farber Cancer Institute

Q10

CDK4/6贬抑剂用于HR+/HER2-早期乳腺癌接济诊治联系东谈主群分析

512：Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.

淋投合阴性(N0)HR+/HER2-早期乳腺癌(EBC)患者(pts)的基线(BL)特征和疗效极端：NATALEE测验

讲者: Denise A. Yardley, MD | Sarah Cannon Research Institute

LBA507：Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

ctDNA检测在monarchE测验中的预后价值

讲者:Sherene Loi, MD, PhD | Peter MacCallum Cancer Centre

投票问题

民众简介

张剑 教师

复旦大学附属肿瘤病院 肿瘤内科主任医师、博导、一期临床斟酌病房实檀越任

复旦大学附属肿瘤病院福建病院临床斟酌中心主任/肿瘤内科常务副主任

中国老年保健协会肿瘤防治与临床斟酌专科委员会主委

长江学术带乳腺定约 YBCSG主委

上海市抗癌协会肿瘤药物临床斟酌专科委员会候任主委

中国抗癌协会乳腺癌专科委员会常委

中国抗癌协会乳腺癌专科委员会青委会副召集东谈主

中国斟酌型病院协会乳腺专科委员会青委会副主委

国度抗肿瘤药物临床专揽监测青委会副主委

上海市抗癌协会肿瘤腹黑病学专科委员会副主委

CSCO肿瘤支撑与康复诊治民众委员会常委

中国康复医学会肿瘤康复专科委员会常委

CSCO后生民众委员会常委

CSCO乳腺癌民众委员会 委员

中国抗癌协会肿瘤临床斟酌解决学专科委员会委员

上海“医苑新星”杰青东谈主才获取者

国度食物药品监督解决总局CDE首批化药临床兼职审评员

获2023 十大医学时尚民众、2023“东谈主民好大夫”隆起孝敬奖

精彩资讯等你来

* 此文仅用于向医学东谈主士提供科学信息，不代表本平台不雅点